Cardiovascular Revascularization Medicine
Volume 11, Issue 1 , Pages 41-51, January 2010

Day 1 care in patients with non-ST-segment elevation myocardial infarction☆☆☆

  • Deepak Thomas

      Affiliations

    • Brigham and Women's Hospital, Nuclear Cardiology, Boston, MA, USA
    • ,
  • Robert P. Giugliano

      Affiliations

    • TIMI Study Group, Brigham and Women's Hospital, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. TIMI Study Office, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA. Tel.: +1 617 278 0145; fax: +1 617 734 7329.

Received 15 May 2009; received in revised form 13 July 2009; accepted 13 July 2009.

Abstract 

In 2007, the American College of Cardiology/American Heart Association and the European Society of Cardiology updated their guidelines for the management of patients with non-ST-segment elevation myocardial infarction (NSTEMI). Based on evidence from recent clinical studies, both 2007 guidelines recommend early risk stratification, administration of appropriate pharmacologic therapy, and selective use of percutaneous coronary intervention in order to reduce morbidity and mortality in these patients. In this article, we focus on management of patients with NSTEMI during the first 24 h of presentation and present a clinical scenario to illustrate the current guidelines-based management strategy.

Keywords: Abciximab, Antiplatelet therapy, Bivalirudin, Enoxaparin, Eptifibatide, Glycoprotein IIb/IIIa inhibitors, Non-ST-segment elevation myocardial infarction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Robert P. Giugliano: Research grant support from Daiichi-Sankyo, Merck, Novartis, Schering-Plough; consultant/speaker's bureau for Bristol-Myers Squibb, HeartScape, Merck, Pfizer, Sanofi-Aventis, Schering-Plough.

☆☆ Editorial assistance for this manuscript was provided by Rina Kleege, MS, and funded by Schering-Plough Corporation, Kenilworth, NJ.

PII: S1553-8389(09)00246-2

doi:10.1016/j.carrev.2009.07.005

Cardiovascular Revascularization Medicine
Volume 11, Issue 1 , Pages 41-51, January 2010

Article Tools

* Image Usage & Resolution